UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 85 filers reported holding UROGEN PHARMA LTD in Q2 2020. The put-call ratio across all filers is 1.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $343,245 | +35.4% | 24,500 | 0.0% | 0.03% | +60.0% |
| Q2 2023 | $253,575 | +12.0% | 24,500 | 0.0% | 0.02% | +5.3% |
| Q1 2023 | $226,380 | +4.2% | 24,500 | 0.0% | 0.02% | 0.0% |
| Q4 2022 | $217,315 | +6.5% | 24,500 | 0.0% | 0.02% | +18.8% |
| Q3 2022 | $204,000 | +1.5% | 24,500 | 0.0% | 0.02% | -11.1% |
| Q2 2022 | $201,000 | -5.6% | 24,500 | 0.0% | 0.02% | +12.5% |
| Q1 2022 | $213,000 | -8.6% | 24,500 | 0.0% | 0.02% | +6.7% |
| Q4 2021 | $233,000 | -43.4% | 24,500 | 0.0% | 0.02% | -40.0% |
| Q3 2021 | $412,000 | +10.2% | 24,500 | 0.0% | 0.02% | +19.0% |
| Q2 2021 | $374,000 | -21.6% | 24,500 | 0.0% | 0.02% | -22.2% |
| Q1 2021 | $477,000 | +8.2% | 24,500 | 0.0% | 0.03% | +17.4% |
| Q4 2020 | $441,000 | -6.8% | 24,500 | 0.0% | 0.02% | -11.5% |
| Q3 2020 | $473,000 | -26.1% | 24,500 | 0.0% | 0.03% | -31.6% |
| Q2 2020 | $640,000 | +46.5% | 24,500 | 0.0% | 0.04% | +2.7% |
| Q1 2020 | $437,000 | – | 24,500 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
| Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
| Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
| MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
| DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
| SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
| BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
| Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |